Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer

NCT04153799 | Unknown Phase 1

• 1 other identifier: B2019-136-01
• Study Type: interventional
• Target: 11
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a clinical study on the safety, efficacy and I phase of single center, single arm, open-dose climbing, intravenous infusion of Anti- Epidermal growth factor receptor(EGFR) Chimeric Antigen Receptor(CAR) T cells modified by C-X-C Chemokine receptor type 5(CXCR 5) in patients with advanced adult non-small cell lung cancer(NSCLC).

Conditions

Non Small Cell Lung Cancer

Keywords

EGFR; CAR-T cells; NSCLC

Outcome Measures

Primary Outcomes (2)

• Safety by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

  The type, frequency, severity, and duration of adverse events as a result of EGFR CAR T cells infusion will be summarized.

  In CAR-T cells infusion, up to 52 weeks.

• Objective Response Rate (ORR)

  Per Response Evaluation Criteria in Solid Tumours (RECIST 1.1) assessed by MRI or CT. ORR is the percentage of patients at Complete Response (CR) or Partial Response (PR) (according to independent review), prior to progression or further anti-cancer therapy.

  In CAR-T cells infusion, up to 52 weeks.

Secondary Outcomes (3)

• Peak Plasma Concentration (Cmax) of CAR T cells in patients.

  In CAR-T cells infusion, up to 6 weeks.

• Peak plasma time (Tmax) of CAR T cells in patients.

  In CAR-T cells infusion, up to 6 weeks.

• Area under the plasma concentration versus time curve (AUC) of CAR T cells in patients.

  In CAR-T cells infusion, up to 6 weeks.

Other Outcomes (3)

• Duration of Response (DOR)

  In CAR-T cells infusion, up to 52 weeks.

• Time to Response (TTR)

  In CAR-T cells infusion, up to 52 weeks.

• Progression-Free Survival (PFS)

  In CAR-T cell infusion, up to 52 weeks.

Study Arms (1)

EGFR CAR-T

EXPERIMENTAL

Group: 3 dose levels

Biological: CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells

Interventions

CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells BIOLOGICAL

The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6 / kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.

EGFR CAR-T

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All subjects or legal guardians must sign the informed consent form approved by the ethics committee in writing before starting any screening procedure;
• Years to 75 Years, Histologically or cytologically confirmed Routine treatment of patients with advanced non-small cell lung cancer;
• After the signature of the informed consent and prior to the collection of a single nuclear cell, the immuno- histochemical test must determine that the expression of EGFR in the tumor site of the patient reaches the positive standard and the score is 2 + or more;
• Pathological results suggest that CXCL13 factor positive rate ≥ 10 %;
• According to RECIST 1.1. The patient has at least one tumor lesion that can be measured (Results available within one month prior to screening period);
• Expected survival time ≥ 12 weeks;
• The Eastern oncology group strength status score (ECOG) was 0-1;
• Patients must have evidence of adequate hepatic and renal function as evidenced by the following laboratory parameters: Serum creatinine≤ 1.6 mg/ml or the creatinine clearance ≥ 40 ml/min/1.73m. Total bilirubin \< 1.5 times upper limits of normal;
• The hemodynamics determined by echocardiography or multichannel radionuclide angiography(MUGA) are stable and the left ventricular ejection fraction (LVEF)≥50%;
• Have sufficient bone marrow reserves (subjects can meet this requirement through blood transfusion), defined as: The number of white blood cells should not be less than 2 × 10\^9/L;Platelet≥100 x 10\^9/L; Hemoglobin ≥100 g/L;
• If the patient uses the following drugs, the following conditions must be met:
• Glucocorticoid: The therapeutic dose of glucocorticoid must be stopped 2 weeks before the EGFR CAR-T infusion. However, the following physiological replacement doses of glucocorticoids are allowed: 12 mg/m2 / dihydrogenated cortisone or equivalent; Immunosuppressive drugs: any immunosuppressive drugs must be stopped before they are selected for 4 weeks; Stop using granulocyte colony factor a week before plasmaphoresis.
• Women of childbearing age and all male subjects must agree to use effective contraceptive methods for at least 52 weeks after EGFR CAR-T infusion, and until two consecutive PCR tests show that CAR-T cells are no longer present in the body.

You may not qualify if:

• Patients who have previously received any gene therapy product treatment, including CAR-T treatment;
• Patients with uncontrolled hypertension (\> 160/95), unstable coronary artery disease confirmed by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure(\>New York Heart Association Class II) or myocardial infarction within 6 months before cell infusion;
• Patients with severe liver and kidney dysfunction or consciousness disorders;
• Patients who had undergone chemotherapy other than lymphocyte clearance chemotherapy within 14 days before the EGFR CAR-T infusion;
• Screening of patients who had received other research drugs within 30 days before;
• Patients undergoing radiotherapy within 2 weeks before infusion;
• Patients with active hepatitis B: HBVDNA \>1000 cps/ml;
• Patients with HIV antibody, hepatitis C antibody, syphilis spirocyte positive；
• Patients with The sputum smear and tuberculosis infection T cell test positive;
• Patients with Interstitial lung disease or pneumonia;
• Patients with acute life-threatening bacteria, viruses or fungal infections that have not yet been controlled(for example, before transfusion ≤ 72 hours of blood culture positive);
• Patients with central nervous system metastasis (after cerebral metastasis treatment is stable for more than 4 weeks and patients with asymptomatic brain metastasis do not need treatment), pericardial metastasis accompanied by a large amount of pericardial effusion;
• Patients with a previous or concurrent second tumor, with the following exceptions:
• Adequate treatment of basal or squamous cell carcinoma(adequate wound healing prior to entry into the study);In situ cancer of the cervix or breast cancer with no signs of recurrence at least three years prior to the study following curable treatment; The primary malignant tumor has been completely removed and has been completely relieved for 5 years.
• Pregnant or lactating women;

Sponsors & Collaborators

• Sun Yat-sen University: lead
• Guangzhou Bio-gene Technology Co., Ltd: collaborator

Study Sites (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Yuxiang Ma, M.D.

CONTACT

86 020 87343894; mayx@sysucc.org.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, Medical doctor

Study Record Dates

• First Submitted: October 9, 2019
• First Posted: November 6, 2019
• Study Start: November 1, 2019
• Primary Completion: December 1, 2021
• Study Completion: December 1, 2022
• Last Updated: May 12, 2020

Record last verified: 2020-05

Locations

CN (1)